[go: up one dir, main page]

WO2014172653A3 - Anti-notch1 antibodies - Google Patents

Anti-notch1 antibodies Download PDF

Info

Publication number
WO2014172653A3
WO2014172653A3 PCT/US2014/034673 US2014034673W WO2014172653A3 WO 2014172653 A3 WO2014172653 A3 WO 2014172653A3 US 2014034673 W US2014034673 W US 2014034673W WO 2014172653 A3 WO2014172653 A3 WO 2014172653A3
Authority
WO
WIPO (PCT)
Prior art keywords
notch1
antibodies
notch1 antibodies
disorders
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/034673
Other languages
French (fr)
Other versions
WO2014172653A2 (en
Inventor
Heidi Okamura
Alisa C. Bell
Ting Chen
Feng Jiang
Jie Lin
Ronan O'hagan
Laura POLING
Theresa PROIA
William M WINSTON, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveo Pharmaceuticals Inc
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of WO2014172653A2 publication Critical patent/WO2014172653A2/en
Publication of WO2014172653A3 publication Critical patent/WO2014172653A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Monoclonal antibodies that bind and inhibit biological activities of human Notch1 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation or over-expression of Notch1.
PCT/US2014/034673 2013-04-19 2014-04-18 Anti-notch1 antibodies Ceased WO2014172653A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361814168P 2013-04-19 2013-04-19
US61/814,168 2013-04-19

Publications (2)

Publication Number Publication Date
WO2014172653A2 WO2014172653A2 (en) 2014-10-23
WO2014172653A3 true WO2014172653A3 (en) 2015-01-08

Family

ID=50942790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/034673 Ceased WO2014172653A2 (en) 2013-04-19 2014-04-18 Anti-notch1 antibodies

Country Status (1)

Country Link
WO (1) WO2014172653A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091641A2 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008150525A1 (en) * 2007-06-04 2008-12-11 Genentech, Inc. Anti-notch1 nrr antibodies and methods using same
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2011088215A2 (en) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2012003472A1 (en) * 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222590A1 (en) 2005-04-05 2006-10-05 Murray Robinson Directed complementation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008091641A2 (en) * 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2008150525A1 (en) * 2007-06-04 2008-12-11 Genentech, Inc. Anti-notch1 nrr antibodies and methods using same
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2011088215A2 (en) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
WO2012003472A1 (en) * 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies

Also Published As

Publication number Publication date
WO2014172653A2 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2011143318A3 (en) Anti-fgfr2 antibodies
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
MX2015007751A (en) Anti-gdf15 antibodies.
HK1250238A1 (en) Anti-angptl8 antibodies and uses thereof
HK1257056A1 (en) Anti-dll3 antibody drug conjugates and methods of use
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2014159595A3 (en) Human antibodies to nav1.7
MX2016003129A (en) Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1.
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
HK1249405A1 (en) Anti-dll3 chimeric antigen receptors and methods of use
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
MX2016005763A (en) Novel anti-claudin antibodies and methods of use.
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
WO2014152006A3 (en) Anti-hepcidin antibodies and uses thereof
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX2015013166A (en) Dual specific binding proteins directed against il-1 beta and il-17.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
WO2014108484A3 (en) Combination therapy of anti-her3 and anti-her2 antibodies
MX2015008534A (en) ANTI- INTEGRIN ß1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF.
MX2014001766A (en) Neuregulin antibodies and uses thereof.
HK1206984A1 (en) Combination therapy of anti-mif antibodies and glucocorticoids
WO2012166659A3 (en) Anti-emr1 antibodies
WO2014172653A3 (en) Anti-notch1 antibodies

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14730253

Country of ref document: EP

Kind code of ref document: A2